|Mr. Patrick J. McEnany||Co-Founder, Chairman, Chief Exec. Officer and Pres||496.56k||N/A||70|
|Ms. Alicia Grande CPA, CMA||Chief Financial Officer, Chief Accounting Officer, VP and Treasurer||326.6k||N/A||46|
|Dr. Steven R. Miller Ph.D.||Chief Operating Officer and Chief Scientific Officer||394.2k||N/A||55|
|Dr. Gary Ingenito M.D., Ph.D.||Chief Medical Officer and Head of Regulatory Affairs||375.83k||N/A||61|
|Mr. Brian Elsbernd||Sr. VP of Legal and Compliance||N/A||N/A||53|
Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for people with rare debilitating diseases. Its lead product candidate is Firdapse, a proprietary form of amifampridine phosphate, which is in second Phase III clinical trials for the treatment of patients with Lambert-Eaton Myasthenic syndrome; and is in small blinded clinical trial to treat Congenital Myasthenic syndromes, as well as is in Phase II/III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis. The company also develops CPP-115, a gamma-aminobutyric acid aminotransferase inhibitor that is in Phase Ib clinical trial for the treatment of epilepsy, infantile spams, and Tourettes disorder; and CPP-109 to treat Tourettes disorder. It has a strategic collaboration with BioMarin Pharmaceutical Inc. for the development of Firdapse. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Catalyst Pharmaceuticals, Inc.’s ISS Governance QualityScore as of May 1, 2017 is 7. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 10; Compensation: 6.